speb/financial-data huggingface dataset:
SURG.V cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: -161507.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Net PPE: 54973098.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 52032914.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 4144000.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 4144000.00
SURG.V income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -640733.00
SURG.V income_statement (quarterly, 2025-06-30) — Normalized Income: -650454.00
SURG.V cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -658759.00
SURG.V income_statement (quarterly, 2025-06-30) — Operating Income: -644167.00
SURG.V income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 290979913.00
SURG.V income_statement (quarterly, 2025-06-30) — Other Gand A: 205445.00
SURG.V income_statement (quarterly, 2025-06-30) — Other Income Expense: -12652.00
SURG.V income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -12652.00
SURG.V income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 30975.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Other Properties: 54955303.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Other Receivables: 3780.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Payables: 87736.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 120236.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 233904.00
SURG.V income_statement (quarterly, 2025-06-30) — Pretax Income: -650454.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Receivables: 247217.00
SURG.V income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 7878.00
SURG.V income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 7878.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -35798563.00
SURG.V income_statement (quarterly, 2025-06-30) — Salaries And Wages: 353704.00
SURG.V income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 46165.00
SURG.V income_statement (quarterly, 2025-06-30) — Selling General And Administration: 605314.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Share Issued: 290979913.00
SURG.V cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 369956.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 52032914.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 52032914.00
SURG.V income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SURG.V income_statement (quarterly, 2025-06-30) — Tax Provision: 0.00
SURG.V income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 243437.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Assets: 56514956.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 52032914.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Debt: 44451.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 52032914.00
SURG.V income_statement (quarterly, 2025-06-30) — Total Expenses: 644167.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 4482042.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 54973098.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 4163504.00
SURG.V balance_sheet (quarterly, 2025-06-30) — Working Capital: 1223320.00
SURG.V income_statement (quarterly, 2025-09-30) — +Operating Expense: 742596.00
SURG.V income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1243903.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Accumulated Depreciation: -135962.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 14009564.00
SURG.V income_statement (quarterly, 2025-09-30) — Basic Average Shares: 323128607.00
SURG.V income_statement (quarterly, 2025-09-30) — Basic EPS: 0.00
SURG.V cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 1060737.00
SURG.V cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -4063987.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 37268.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Capital Stock: 83467979.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 8185511.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 8185511.00
SURG.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 10256619.00
SURG.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -4066987.00
SURG.V cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 935142.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -7183.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Payable: 1207663.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 1207663.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 69424.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Receivables: 32275.00
SURG.V cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 1302179.00
SURG.V cash_flow (quarterly, 2025-09-30) — Changes In Cash: 7124774.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Common Stock: 83467979.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 61582667.00
SURG.V cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 10375106.00
SURG.V income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 7879.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 39000.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Assets: 8564933.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 24947.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 24947.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Deferred Liabilities: 505305.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1858151.00
SURG.V cash_flow (quarterly, 2025-09-30) — Depreciation: 7879.00
SURG.V cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 7879.00
SURG.V cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 7879.00
SURG.V income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 323128607.00
SURG.V income_statement (quarterly, 2025-09-30) — Diluted EPS: 0.00
SURG.V income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -96313.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 44996.00
SURG.V income_statement (quarterly, 2025-09-30) — EBIT: -94471.00
SURG.V income_statement (quarterly, 2025-09-30) — EBITDA: -86592.00
SURG.V cash_flow (quarterly, 2025-09-30) — End Cash Position: 8185511.00
SURG.V cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 10256619.00
SURG.V cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -3128845.00
SURG.V income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 397046.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Gross PPE: 59168168.00
SURG.V income_statement (quarterly, 2025-09-30) — Gross Profit: -7879.00
SURG.V income_statement (quarterly, 2025-09-30) — Interest Expense: 1842.00
SURG.V income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 1842.00
SURG.V income_statement (quarterly, 2025-09-30) — Interest Income: 21815.00
SURG.V income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 21815.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Invested Capital: 61582667.00
SURG.V cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -4066987.00
SURG.V cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 10375106.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 12321.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 12321.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Machinery Furniture Equipment: 152659.00
SURG.V cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 10375106.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -96313.00
SURG.V cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -96313.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Interest Income: 19973.00
SURG.V income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 19973.00
SURG.V cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -118487.00
SURG.V cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -3000.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Net PPE: 59032206.00
SURG.V cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -4063987.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 61582667.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Liabilities: 4144000.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 4144000.00
SURG.V income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -86592.00
SURG.V income_statement (quarterly, 2025-09-30) — Normalized Income: -96313.00
SURG.V cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 935142.00
SURG.V income_statement (quarterly, 2025-09-30) — Operating Income: -750475.00
SURG.V income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 345414484.00
SURG.V income_statement (quarterly, 2025-09-30) — Other Gand A: 45060.00
SURG.V income_statement (quarterly, 2025-09-30) — Other Income Expense: 634189.00
SURG.V cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -630589.00
SURG.V income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 634189.00
SURG.V income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 242531.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Other Properties: 59015509.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Other Receivables: 3780.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Payables: 1288899.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 1327899.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 164480.00
SURG.V income_statement (quarterly, 2025-09-30) — Pretax Income: -96313.00
SURG.V cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -4063987.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Receivables: 214942.00
SURG.V income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 7879.00
SURG.V income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 7879.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -35894876.00
SURG.V income_statement (quarterly, 2025-09-30) — Salaries And Wages: 351986.00
SURG.V income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 103019.00
SURG.V income_statement (quarterly, 2025-09-30) — Selling General And Administration: 500065.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Share Issued: 345414484.00
SURG.V cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 351986.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 61582667.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 61582667.00
SURG.V income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
SURG.V income_statement (quarterly, 2025-09-30) — Tax Provision: 0.00
SURG.V income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 211162.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Assets: 67597139.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 61582667.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Debt: 37268.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 61582667.00
SURG.V income_statement (quarterly, 2025-09-30) — Total Expenses: 750475.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 6014472.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 59032206.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 4156321.00
SURG.V balance_sheet (quarterly, 2025-09-30) — Working Capital: 6706782.00
SURG.V income_statement (quarterly, 2025-12-31) — +Operating Expense: 1100719.00
SURG.V income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 489677.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -137059.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 14188787.00
SURG.V income_statement (quarterly, 2025-12-31) — Basic Average Shares: 326225863.00
SURG.V income_statement (quarterly, 2025-12-31) — Basic EPS: -0.01
SURG.V cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 8185511.00
SURG.V cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -2247666.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 27951.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Capital Stock: 83467979.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 4295620.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 4295620.00
SURG.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 0.00
SURG.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -2247666.00
SURG.V cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -1642225.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: -9317.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Payable: -784834.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -784834.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 49552.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Receivables: -126989.00
SURG.V cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -871588.00
SURG.V cash_flow (quarterly, 2025-12-31) — Changes In Cash: -3889891.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Common Stock: 83467979.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 59938553.00
SURG.V cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 0.00
SURG.V income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 7878.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 45500.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Assets: 4752479.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 27951.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 27951.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 1370904.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1941920.00
SURG.V cash_flow (quarterly, 2025-12-31) — Depreciation: 7878.00
SURG.V cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 7878.00
SURG.V cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 7878.00
SURG.V income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 326225863.00
SURG.V income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.01
SURG.V income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -1823337.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Current: 7888.00
SURG.V income_statement (quarterly, 2025-12-31) — EBIT: -1823246.00
SURG.V income_statement (quarterly, 2025-12-31) — EBITDA: -1815368.00
SURG.V cash_flow (quarterly, 2025-12-31) — End Cash Position: 4295620.00
SURG.V cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 0.00
SURG.V cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -3889891.00
SURG.V income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 379244.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Gross PPE: 61409053.00
SURG.V income_statement (quarterly, 2025-12-31) — Gross Profit: -7878.00
SURG.V income_statement (quarterly, 2025-12-31) — Interest Expense: 91.00
SURG.V income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 91.00
SURG.V income_statement (quarterly, 2025-12-31) — Interest Income: 33868.00
SURG.V income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 33868.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Invested Capital: 59938553.00
SURG.V cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -2247666.00
SURG.V cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 0.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 0.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 152659.00
SURG.V cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 0.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -1823337.00
SURG.V cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -1823337.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Interest Income: 33777.00
SURG.V income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 33777.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Net PPE: 61271994.00
SURG.V cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -2247666.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 59938553.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 4144000.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 4144000.00
SURG.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -1815368.00
SURG.V income_statement (quarterly, 2025-12-31) — Normalized Income: -1823337.00
SURG.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -1642225.00
SURG.V income_statement (quarterly, 2025-12-31) — Operating Income: -1108597.00
SURG.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 345414484.00
SURG.V income_statement (quarterly, 2025-12-31) — Other Gand A: 86539.00
SURG.V income_statement (quarterly, 2025-12-31) — Other Income Expense: -748517.00
SURG.V cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 752117.00
SURG.V income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -748517.00
SURG.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 604692.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Other Properties: 61256394.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Other Receivables: 2520.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Payables: 497565.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 543065.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 114928.00
SURG.V income_statement (quarterly, 2025-12-31) — Pretax Income: -1823337.00
SURG.V cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -2247666.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Receivables: 341931.00
SURG.V income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 7878.00
SURG.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 7878.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -37718213.00
SURG.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 292705.00
SURG.V income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 116783.00
SURG.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 496027.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 345414484.00
SURG.V cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 292705.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 59938553.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 59938553.00
SURG.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
SURG.V income_statement (quarterly, 2025-12-31) — Tax Provision: 0.00
SURG.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 339411.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 66024473.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 59938553.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Debt: 27951.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 59938553.00
SURG.V income_statement (quarterly, 2025-12-31) — Total Expenses: 1108597.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 6085920.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 61271994.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 4144000.00
SURG.V balance_sheet (quarterly, 2025-12-31) — Working Capital: 2810559.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -3939366000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 1052545000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -7022000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 16702000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Basic EPS: 0.13
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 1242693000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Cash Dividends Paid: -464000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 50000000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 19844000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Common Stock Issuance: 181305000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 1173000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 16702000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Diluted EPS: 0.13
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 554000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 491234000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: 435331000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 39818000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 1502678000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Interest Income: 6651000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 6651000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 181305000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 80119000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 4325816000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: 181305000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Net Income Discontinuous Operations: -341536000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Net Preferred Stock Issuance: 159975000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 656000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 81107000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 32728000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: 1000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 1842000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 4893000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: 1314000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Other Payable: 162304000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Pension And Employee Benefit Expense: 1039000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 46619000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Preferred Securities Outside Stock Equity: 70000000.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Preferred Stock Issuance: 159975000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 640667000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
SURYALAXMI.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: 0.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 721312000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 1006000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 1006000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 129625000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 808548000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 255713000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 295531000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 69213000.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 0.00
SURYALAXMI.NS balance_sheet (annual, 2022-03-31) — Work In Process: 355605000.00
SURYALAXMI.NS income_statement (annual, 2022-03-31) — Write Off: 52062000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — +Operating Expense: 1823074000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — +Total Revenue: 8314976000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 1313485000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 1395709000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -4043791000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 1052545000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -17815000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Amortization: 109000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Assets Held For Sale Current: 7484000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 54830000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 18805000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Basic EPS: 5.53
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 69844000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1270581000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -247469000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 984000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 205783000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 2800000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 4326000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 2800000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 73619000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 126268000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 2167000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Payable: 105505000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Receivables: 87447000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 398281000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -7044000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Common Stock: 205783000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 2630301000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Common Stock Issuance: 0.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 65803000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 6031661000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Assets: 3865620000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 984000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Debt: 1321626000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1322610000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 2898952000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 39167000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Depreciation: 175618000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 175618000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 175618000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 175509000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 18805000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Diluted EPS: 5.53
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 104011000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 366000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — EBIT: 350742000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — EBITDA: 526360000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — End Cash Position: 62800000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -975127000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 582521000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 745673000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: -4290000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 53235000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 1733000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 1413524000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 6559825000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Gross Profit: 2283315000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Interest Expense: 163712000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 163712000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Interest Income: 11907000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 11907000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -287637000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 7970000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Inventory: 1499425000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 4542626000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -25059000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 54830000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Issuance Of Capital Stock: 0.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 11451000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 80119000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 0.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 590699000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 590699000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 11451000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: -419206000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 88257000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 4399501000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: 0.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Net Debt: 1909525000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income: 104011000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 104011000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 127213000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income Discontinuous Operations: -23202000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 104011000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 127213000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 159733000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 104011000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Interest Income: -233028000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -77418000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: -686983000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: -407755000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -233028000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Other Investing Changes: -77418000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Net PPE: 2516034000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: 44389000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Preferred Stock Issuance: 11451000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: -279228000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 2628568000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Revenue: 0.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 267421000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 88257000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 53332000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 610798000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Normalized Income: 184645557.85
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 993142000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Operating Income: 460241000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Operating Revenue: 8314976000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 18805290.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 450840000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 16658000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 36234000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 1733000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Inventories: 4879000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 290047000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 53332000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 1506000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 956045000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Payable: 190601000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Properties: 743821000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 209174000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1526000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Other Special Charges: 66931000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Payables: 1504452000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Pension And Employee Benefit Expense: -2721000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 41933000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Preferred Securities Outside Stock Equity: 64892000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Preferred Stock Issuance: 11451000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 508392000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Pretax Income: 187030000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -77418000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -247469000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 550651000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 6031661000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 175618000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 2038000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 2038000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: -419206000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 217042000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 912559000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 291858000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 170716000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 223951000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Share Issued: 18805290.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Special Income Charges: -84438000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 2630301000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 2628568000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -27005442.15
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Tax Provision: 59817000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.32
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 24068000.00
SURYALAXMI.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -33578000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Assets: 6540522000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 3221000000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Debt: 1913309000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 2630301000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Total Expenses: 7854735000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 3910221000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 2674902000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 1011269000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 81223000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 0.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Total Unusual Items: -84438000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -84438000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Work In Process: 361374000.00
SURYALAXMI.NS balance_sheet (annual, 2023-03-31) — Working Capital: 966668000.00
SURYALAXMI.NS income_statement (annual, 2023-03-31) — Write Off: 17507000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — +Operating Expense: 1835162000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — +Total Revenue: 7617126000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 1764612000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 1795205000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -4138726000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 1052545000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -17954000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Amortization: 20000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 6778000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 154075000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 18805000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Basic EPS: 1.92
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 62800000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1288640000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -333703000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 0.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 205783000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 1759000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 3813000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 1759000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -400552000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 50077000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -75188000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Payable: 452680000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -407138000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: -370592000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Changes In Cash: -61041000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Common Stock: 205783000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 2660520000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 0.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 42714000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 5402440000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Assets: 4463027000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 0.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Debt: 1577789000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1577789000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 3556847000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 40882000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Depreciation: 180652000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 180652000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 180652000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 180632000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 18805000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Diluted EPS: 1.92
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 36075000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 146000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — EBIT: 251554000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — EBITDA: 432206000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — End Cash Position: 1759000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: -1181000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 513099000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: -139651000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 946000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 56596000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 1851000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 1813159000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 6799173000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Gross Profit: 2214686000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Interest Expense: 189312000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 189312000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Interest Income: 9135000.00
SURYALAXMI.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 9135000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -277397000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 2432000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Inventory: 1899977000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 4853245000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -253912000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 154075000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 0.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 220175000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 80119000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 0.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 614936000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 614936000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 220175000.00
SURYALAXMI.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -287956000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 105111000.00
SURYALAXMI.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 4586320000.00